Vera Therapeutics Inc (OQ:VERA)

Business Focus: Biotechnology & Medical Research

May 07, 2024 04:38 pm ET
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,000 shares of Class A common...
Apr 02, 2024 08:00 am ET
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced two presentations of data from...
Mar 20, 2024 07:30 am ET
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today reported its business highlights and...
Feb 28, 2024 04:20 pm ET
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management...
Feb 02, 2024 08:00 am ET
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management...
Feb 01, 2024 04:05 pm ET
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the closing of its previously announced...
Jan 29, 2024 11:50 pm ET
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an upsized underwritten public...
Jan 29, 2024 06:15 am ET
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject...
Jan 25, 2024 08:31 am ET
Thinking about trading options or stock in TAL Education, Vera Therapeutics, MarineMax, General Motors, or Boyd Gaming?
NEW YORK, Jan. 25, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TAL, VERA, HZO, GM, and BYD.
Jan 25, 2024 06:30 am ET
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced positive 72-week data from the open label...
Jan 08, 2024 08:01 am ET
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the appointments of two industry veterans...
Jan 08, 2024 08:00 am ET
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced it will host an in-person R&D day featuring...
Dec 27, 2023 08:00 am ET
Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management...
Nov 09, 2023 08:00 am ET
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today reported its business highlights and...
Nov 04, 2023 10:00 am ET
Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the presentation of three posters –...
Oct 30, 2023 08:00 am ET
Vera Therapeutics Scheduled to Present at November Investor Conferences
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management...
Oct 13, 2023 10:22 am ET
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that three abstracts on the...
Aug 31, 2023 08:00 am ET
Vera Therapeutics Scheduled to Present at September Investor Conferences
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management...
Aug 10, 2023 08:00 am ET
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business updates and...
Jun 20, 2023 09:31 am ET
Thinking about buying stock in iCAD, Voxeljet, NeoVolta, Vera Therapeutics, or Nio Inc?
NEW YORK, June 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ICAD, VJET, NEOV, VERA, and NIO.
Jun 17, 2023 10:10 am ET
Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) C
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the Phase 2b ORIGIN clinical trial of...
Jun 15, 2023 04:44 pm ET
Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced it will host a post-ERA data...
Jun 12, 2023 09:31 am ET
Thinking about trading options or stock in Xpeng Inc, Apple, NVIDIA, Chinook Therapeutics, or Vera Therapeutics?
NEW YORK, June 12, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XPEV, AAPL, NVDA, KDNY, and VERA.
Jun 08, 2023 08:00 am ET
Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management...
Jun 07, 2023 08:00 am ET
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced initiation of the pivotal Phase 3...
May 11, 2023 07:30 am ET
Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business updates and...
May 04, 2023 08:00 am ET
Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced the appointment of Kerry Cooper, M.D.,...
Mar 28, 2023 07:30 am ET
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights for the...
Feb 27, 2023 04:05 pm ET
Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will...
Feb 06, 2023 10:02 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA
NEW YORK, Feb. 6, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vera Therapeutics, Inc. ("Vera" or the "Company") (NASDAQ: VERA).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Feb 06, 2023 04:05 pm ET
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
Vera Therapeutics, Inc. (NasdaqGM: VERA; “Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the closing of its previously...
Feb 04, 2023 04:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA
Pomerantz LLP is investigating claims on behalf of investors of Vera Therapeutics, Inc. (“Vera” or the “Company”) (NASDAQ: VERA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Feb 01, 2023 09:51 pm ET
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
Vera Therapeutics, Inc., (NasdaqGM: VERA; “Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its...
Feb 01, 2023 04:01 pm ET
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock
Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has commenced a public offering,...
Jan 30, 2023 06:00 am ET
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Place
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced results from a prespecified per-protocol...
Jan 25, 2023 08:00 am ET
Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that it will host a virtual key opinion...
Jan 21, 2023 09:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA
Pomerantz LLP is investigating claims on behalf of investors of Vera Therapeutics, Inc. (“Vera” or the “Company”) (NASDAQ: VERA).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jan 19, 2023 11:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA
NEW YORK, Jan. 20, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vera Therapeutics, Inc. ("Vera" or the "Company") (NASDAQ: VERA).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jan 12, 2023 06:03 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vera Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vera Therapeutics, Inc. (“Vera” or “the Company”) (NASDAQ:
Jan 11, 2023 11:49 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA
NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vera Therapeutics, Inc. ("Vera" or the "Company") (NASDAQ: VERA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jan 03, 2023 04:01 pm ET
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced the Phase 2b ORIGIN clinical trial of...
Dec 20, 2022 04:05 pm ET
Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will...
Nov 22, 2022 07:30 am ET
Vera Therapeutics to Present at Upcoming Investor Conferences
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will...
Nov 17, 2022 07:30 am ET
Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host a key opinion leader...
Nov 09, 2022 07:30 am ET
Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial...
Nov 05, 2022 04:50 pm ET
Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus I
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced new clinical data presented on the...
Oct 17, 2022 07:30 am ET
Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropath
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced two new abstracts featuring new clinical data...
Sep 07, 2022 07:30 am ET
Vera Therapeutics to Present at Upcoming Conferences in September 2022
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will...
Aug 10, 2022 07:30 am ET
Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial...
Aug 04, 2022 07:30 am ET
Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will...
Jul 06, 2022 07:30 am ET
Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced completion of patient enrollment in the...
Jun 04, 2022 02:30 pm ET
Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that interim data from the Phase 2 trial...
Jun 02, 2022 07:30 am ET
Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will...
May 20, 2022 04:05 pm ET
Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced new clinical data for its lead product...
May 16, 2022 07:30 am ET
Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial...
May 05, 2022 04:05 pm ET
Vera Therapeutics to Present at Upcoming Conferences in May 2022
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will...
May 03, 2022 04:33 pm ET
Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephro
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced two oral presentations featuring new...
May 02, 2022 07:06 pm ET
Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that interim data from the Phase 2 trial...
Apr 12, 2022 07:30 am ET
Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors
Vera Therapeutics (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, announced today the appointment Michael M. Morrissey, Ph.D.,...
Mar 24, 2022 06:30 am ET
Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial...
Mar 21, 2022 07:30 am ET
Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D., World-Renowned Transplant Nephrologist and Pioneering Kidney Transplant Researcher
Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host a key opinion leader (KOL)...
Mar 17, 2022 07:30 am ET
Vera Therapeutics to Host Business Update Call
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, will host a business update call at 8:00 a.m. ET on...
Mar 01, 2022 07:30 am ET
Vera Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference
Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that Marshall Fordyce, MD, founder...
Feb 14, 2022 04:01 pm ET
Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the closing of its public offering of...
Feb 10, 2022 08:46 am ET
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
Vera Therapeutics, Inc. (“Vera”) (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its public...
Feb 07, 2022 05:24 pm ET
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock
Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has commenced a public offering,...
Jan 18, 2022 07:30 am ET
Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced plans to initiate a Phase 3 clinical trial of...
Jan 04, 2022 07:30 am ET
Vera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that Marshall Fordyce, MD, founder...
Dec 17, 2021 07:30 am ET
Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients
Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives, announced today that it has acquired MAU868, a first-in-class monoclonal...
Dec 14, 2021 07:30 am ET
Vera Therapeutics Announces Appointment of Kimball Hall to Board of Directors
Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Kimball Hall to...
Nov 10, 2021 04:15 pm ET
Vera Therapeutics to Present at Upcoming Investment Conferences in November 2021
Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that Marshall Fordyce, MD, Founder...
Nov 10, 2021 07:15 am ET
Vera Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives, today reported its business highlights and financial results for the quarter...
Nov 04, 2021 04:05 pm ET
Vera Therapeutics Presents Phase 2a Data Showing Atacicept Reduces Serum Gd-IgA1 in Patients with IgA Nephropathy at the American Society of Nephrology Kidney Week 2021
Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives, today presented clinical data for the Company’s lead product candidate,...
Oct 13, 2021 07:30 am ET
Vera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 Annual Meeting
Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives, announced today the upcoming presentation of clinical data for the Company’s...
Sep 09, 2021 07:30 am ET
Vera Therapeutics Hosting Key Opinion Leader Webinar on IgA Nephropathy
Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives, announced today that it is scheduled to host a key opinion leader (KOL) webinar...
Aug 16, 2021 07:30 am ET
Vera Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives, today reported its financial results for the second quarter ended June 30, 2021...
Jul 14, 2021 07:30 am ET
Vera Therapeutics Appoints Sean Grant as Chief Financial Officer
Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Sean Grant, MBA...
Jun 24, 2021 07:15 am ET
Vera Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its financial results for the first...
May 27, 2021 04:05 pm ET
Vera Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that management will provide a...
May 13, 2021 08:52 pm ET
Vera Therapeutics Announces Pricing of Initial Public Offering
Vera Therapeutics, Inc. (“Vera”), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its initial public...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.